Author

Biblio print

Tree Display

AceDB Schema

XML Display

Feedback

Author Report for: Robert J

No contact information in database for Robert J




    Title: The Endothelium Is Both a Target and a Barrier of HDL's Protective Functions
    Robert J, Osto E, von Eckardstein A
    Ref: Cells, 10:, 2021 : PubMed

            

    Title: Genome evolution in the allotetraploid frog Xenopus laevis
    Session AM, Uno Y, Kwon T, Chapman JA, Toyoda A, Takahashi S, Fukui A, Hikosaka A, Suzuki A and Rokhsar DS <64 more author(s)>
    Ref: Nature, 538:336, 2016 : PubMed

            

    Title: The genome of the Western clawed frog Xenopus tropicalis
    Hellsten U, Harland RM, Gilchrist MJ, Hendrix D, Jurka J, Kapitonov V, Ovcharenko I, Putnam NH, Shu S and Rokhsar DS <38 more author(s)>
    Ref: Science, 328:633, 2010 : PubMed

            

    Title: Recommended nomenclature for five mammalian carboxylesterase gene families: human, mouse, and rat genes and proteins
    Holmes RS, Wright MW, Laulederkind SJ, Cox LA, Hosokawa M, Imai T, Ishibashi S, Lehner R, Miyazaki M and Maltais LJ <9 more author(s)>
    Ref: Mamm Genome, 21:427, 2010 : PubMed

            

    Title: Functional study of the 830C>G polymorphism of the human carboxylesterase 2 gene
    Bellott R, Le Morvan V, Charasson V, Laurand A, Colotte M, Zanger UM, Klein K, Smith D, Bonnet J, Robert J
    Ref: Cancer Chemother Pharmacol, 61:481, 2008 : PubMed

            

    Title: Pharmacogenetics of human carboxylesterase 2, an enzyme involved in the activation of irinotecan into SN-38
    Charasson V, Bellott R, Meynard D, Longy M, Gorry P, Robert J
    Ref: Clinical Pharmacology & Therapeutics, 76:528, 2004 : PubMed

            

    Title: Cellular parameters predictive of the clinical response of colorectal cancers to irinotecan. A preliminary study
    Pavillard V, Charasson V, Laroche-Clary A, Soubeyran I, Robert J
    Ref: Anticancer Research, 24:579, 2004 : PubMed

            

    Title: Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38
    Dodds HM, Haaz MC, Riou JF, Robert J, Rivory LP
    Ref: Journal of Pharmacology & Experimental Therapeutics, 286:578, 1998 : PubMed

            

    Title: Pharmacology of irinotecan
    Robert J, Rivory L
    Ref: Drugs Today (Barc), 34:777, 1998 : PubMed

            

    Title: The transformation of irinotecan (CPT-11) to its active metabolite SN-38 by human liver microsomes. Differential hydrolysis for the lactone and carboxylate forms
    Haaz MC, Rivory LP, Riche C, Robert J
    Ref: Naunyn Schmiedebergs Arch Pharmacol, 356:257, 1997 : PubMed

            

    Title: Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydroxycamptothecin (SN-38), by human liver carboxylesterase
    Rivory LP, Bowles MR, Robert J, Pond SM
    Ref: Biochemical Pharmacology, 52:1103, 1996 : PubMed

            

    Title: Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients
    Rivory LP, Riou JF, Haaz MC, Sable S, Vuilhorgne M, Commercon A, Pond SM, Robert J
    Ref: Cancer Research, 56:3689, 1996 : PubMed

            

    Title: Choline uptake and metabolism by nerve cell cultures
    Massarelli R, Yong TY, Froissart C, Robert J
    Ref: Prog Brain Res, 49:89, 1979 : PubMed

            

    Title: Dynamics of phospholipids in cultured cells of neural origin
    Yavin E, Robert J
    Ref: Biochemical Society Transactions, 7:341, 1979 : PubMed

            

    Title: Polar head groups manipulation of phospholipids in cultured neuroblastoma cells
    Robert J, Rebel G, Mandel P, Yavin E
    Ref: Life Sciences, 22:211, 1978 : PubMed

            


Send your questions or comments to :
Mail to: Nicolas Lenfant, Thierry Hotelier, Yves Bourne, Pascale Marchot and Arnaud Chatonnet.
Please cite: Lenfant 2013 Nucleic.Acids.Res. or Marchot Chatonnet 2012 Prot.Pept Lett.
For technical information about these pages see:
ESTHER Home Page and ACEDB Home Page
AcePerl Lincoln Stein Home Page
webmaster

Acknowledgements and disclaimer